Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary
- PMID: 20107305
- DOI: 10.3810/pgm.2010.01.2115
Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary
Abstract
Prasugrel was associated with a statistically significant reduction in rates of cardiac ischemic events in patients with ACS who had undergone PCI. Rates of post-PCI death from cardiovascular causes, nonfatal MI, or nonfatal stroke were also significantly reduced with the use of prasugrel versus clopidogrel. Major bleeding was significantly increased with the use of prasugrel versus clopidogrel. Mortality did not differ significantly between the groups.
Comment on
-
Prasugrel versus clopidogrel in patients with acute coronary syndromes.N Engl J Med. 2007 Nov 15;357(20):2001-15. doi: 10.1056/NEJMoa0706482. Epub 2007 Nov 4. N Engl J Med. 2007. PMID: 17982182 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous